Lanean...
A patent review on PD-1/PD-L1 antagonists: small molecules, peptides and macrocycles (2015–2018)
INTRODUCTION: The protein protein interaction PD1/PD-L1 is an important immune checkpoint and several recently approved monoclonal antibodies show promising anti cancer activities in the clinical practice. However, only a small percentage of cancer patients benefit from PD1/PD-L1 directed mAbs. More...
Gorde:
| Argitaratua izan da: | Expert Opin Ther Pat |
|---|---|
| Egile Nagusiak: | , , , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2018
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6323140/ https://ncbi.nlm.nih.gov/pubmed/30107136 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/13543776.2018.1512706 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|